[go: up one dir, main page]

WO2004082570A3 - Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) - Google Patents

Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) Download PDF

Info

Publication number
WO2004082570A3
WO2004082570A3 PCT/EP2004/002184 EP2004002184W WO2004082570A3 WO 2004082570 A3 WO2004082570 A3 WO 2004082570A3 EP 2004002184 W EP2004002184 W EP 2004002184W WO 2004082570 A3 WO2004082570 A3 WO 2004082570A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
drd2
therapeutics
diagnostics
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002184
Other languages
French (fr)
Other versions
WO2004082570A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2004082570A2 publication Critical patent/WO2004082570A2/en
Publication of WO2004082570A3 publication Critical patent/WO2004082570A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human DRD2 which is associated with the endocrine system and hormone disorders, neurological disorders, respiratory diseases, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone disorders, neurological disorders, respiratory diseases, cancer disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of DRD2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/002184 2003-03-17 2004-03-04 Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) Ceased WO2004082570A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03005469.6 2003-03-17
EP03005469 2003-03-17

Publications (2)

Publication Number Publication Date
WO2004082570A2 WO2004082570A2 (en) 2004-09-30
WO2004082570A3 true WO2004082570A3 (en) 2005-01-27

Family

ID=33016823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002184 Ceased WO2004082570A2 (en) 2003-03-17 2004-03-04 Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)

Country Status (1)

Country Link
WO (1) WO2004082570A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975476C (en) 2015-01-30 2023-10-03 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy
BR112018015590A2 (en) * 2016-01-29 2019-10-01 Oncoceutics Inc g protein coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
KR102128251B1 (en) * 2019-05-27 2020-06-30 사회복지법인 삼성생명공익재단 Biomarker Composition for Diagnosing Colorectal Cancer Specifically Binding to Arginine-methylated Dopamine Receptor D2
CN115068612B (en) * 2021-08-18 2023-05-23 四川大学华西第二医院 Application of DRD2 inhibitor in preparation of medicine for treating diseases related to liver fibrosis

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005040A1 (en) * 1989-09-27 1991-04-18 The United States Of America, Represented By The Secretary, United States Department Of Commerce Cloned genes for human dopamine d2 receptors and cell lines expressing same
WO1996034094A1 (en) * 1995-04-26 1996-10-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-human transgenic animal with modified d2 receptor expression
WO1999066935A1 (en) * 1998-06-20 1999-12-29 Medical Research Council Male contraceptive comprising a prolactin inhibitor and a sex steroid
US20010005724A1 (en) * 1996-12-18 2001-06-28 Cross Dee L. Method for promoting ovulation, parturition, and lactation in mammals
WO2001072741A2 (en) * 2000-03-28 2001-10-04 Knoll Gmbh N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders
WO2002020491A1 (en) * 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazine derivatives and their use as psychotropic agents
US20020123096A1 (en) * 1988-11-18 2002-09-05 Oregon Health Sciences University. Dopamine receptors and genes
WO2003012143A1 (en) * 2001-07-16 2003-02-13 Price Foundation Limited Genes and snps associated with eating disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123096A1 (en) * 1988-11-18 2002-09-05 Oregon Health Sciences University. Dopamine receptors and genes
WO1991005040A1 (en) * 1989-09-27 1991-04-18 The United States Of America, Represented By The Secretary, United States Department Of Commerce Cloned genes for human dopamine d2 receptors and cell lines expressing same
WO1996034094A1 (en) * 1995-04-26 1996-10-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-human transgenic animal with modified d2 receptor expression
US20010005724A1 (en) * 1996-12-18 2001-06-28 Cross Dee L. Method for promoting ovulation, parturition, and lactation in mammals
WO1999066935A1 (en) * 1998-06-20 1999-12-29 Medical Research Council Male contraceptive comprising a prolactin inhibitor and a sex steroid
WO2001072741A2 (en) * 2000-03-28 2001-10-04 Knoll Gmbh N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders
WO2002020491A1 (en) * 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazine derivatives and their use as psychotropic agents
WO2003012143A1 (en) * 2001-07-16 2003-02-13 Price Foundation Limited Genes and snps associated with eating disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, BROWNELL J: "Quinagolide in hyperprolactinaemia", XP002289640, Database accession no. EMB-1998093760 *
LAHTI R A ET AL: "DOPAMINE D-2 RECEPTOR BINDING PROPERTIES OF TRITIATED U-86170 A DOPAMINE RECEPTOR AGONIST", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 202, no. 2, 1991, pages 289 - 291, XP002289638, ISSN: 0014-2999 *
MORO MAKOTO ET AL: "Effects of dopamine D2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemima/anovulation model in rats", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 28, no. 8, August 2001 (2001-08-01), pages 651 - 658, XP002289639, ISSN: 0305-1870 *
REVIEWS IN CONTEMPORARY PHARMACOTHERAPY 1998 UNITED KINGDOM, vol. 9, no. 1, 1998, pages 1 - 75, ISSN: 0954-8602 *

Also Published As

Publication number Publication date
WO2004082570A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2003081258A3 (en) Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
WO2004082570A3 (en) Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2004086047A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2005093423A3 (en) Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004073587A3 (en) Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)
WO2003081234A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens g - protein - coupled receptor 8 (gpr8)
WO2005059504A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor gpr34 (gpr34)
WO2005026736A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a2 (slc22a2)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase